Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Assets (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Current Assets for 5 consecutive years, with $23.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 57.72% to $23.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.0 million, a 57.72% decrease, with the full-year FY2024 number at $43.0 million, down 58.95% from a year prior.
  • Current Assets was $23.0 million for Q3 2025 at Lyra Therapeutics, down from $31.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $122.4 million in Q2 2022 to a low of $23.0 million in Q3 2025.
  • A 5-year average of $72.6 million and a median of $69.4 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 110.42% in 2022, then tumbled 62.09% in 2025.
  • Lyra Therapeutics' Current Assets stood at $47.9 million in 2021, then skyrocketed by 110.42% to $100.8 million in 2022, then grew by 3.96% to $104.8 million in 2023, then tumbled by 58.95% to $43.0 million in 2024, then plummeted by 46.5% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Current Assets are $23.0 million (Q3 2025), $31.1 million (Q2 2025), and $33.9 million (Q1 2025).